Bortezomib






2135 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 9316879 Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 1997 Sep 1
2 10199816 Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. Am J Physiol 1999 Apr 4
3 10363983 Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999 Jun 1 1
4 10499643 The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999 Sep 1
5 11306489 The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001 Apr 1 6
6 11316563 Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001 May 1 3
7 11350913 Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001 May 13
8 11400168 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001 Apr 2-27 3
9 11468181 TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001 Aug 1 5
10 11489836 Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001 Aug 2
11 11494147 The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001 Jul 27 3
12 11516199 Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001 Sep 2
13 11740818 Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001 Dec 11
14 11755313 Ethanol withdrawal induced CYP2E1 degradation in vivo, blocked by proteasomal inhibitor PS-341. Free Radic Biol Med 2002 Jan 1 3
15 11772267 Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. Expert Opin Investig Drugs 2001 Aug 2
16 11861386 Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002 Feb 15 2
17 12010810 Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002 Jun 1 1
18 12170431 Hematologic malignancies: new developments and future treatments. Semin Oncol 2002 Aug 1
19 12226754 The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002 Sep 19 4
20 12391322 Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002 Oct 29 5
21 12393500 Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003 Feb 15 9
22 12492117 PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002 Aug 4
23 12516957 Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002 Dec 1
24 12538487 Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003 Jan 4
25 12548578 Moving disease biology from the lab to the clinic. Cancer 2003 Feb 1 1
26 12631619 The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003 Mar 3
27 12631620 Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003 Mar 3
28 12637321 The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003 Jul 1 2
29 12738240 Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003 May 1
30 12738241 Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003 May 2
31 12738242 Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 2003 May 4
32 12816986 Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003 Jul 1 1
33 12821677 Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003 Sep 5 8
34 12893773 The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003 Nov 15 8
35 12902978 The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003 Aug 7 12
36 12935973 The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003 Aug 3
37 12943815 Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 2003 Jul 8
38 14513055 The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003 Oct 13
39 14555528 Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 2003 Oct 1 2
40 14555532 Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 2003 Oct 1 2
41 14559800 Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003 Oct 1 3
42 14612532 The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 2003 Nov 1 10
43 14627979 Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003 Nov 20 15
44 14688479 Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol Ther 2003 Nov-Dec 11
45 14965369 Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004 Feb 25
46 15004512 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis 2004 Mar 3
47 15010285 Proteasome inhibition induces cytokeratin accumulation in vivo. Exp Mol Pathol 2004 Apr 3
48 15016328 Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 2004 Mar 10
49 15026548 The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004 Mar 6
50 15039284 Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 2004 Jul 15 13